Inhibition of LIFR Blocks Adiposity-Driven Endometrioid Endometrial Cancer Growth
Authors:
- Logan BlankenshipLBLogan Blankenship
- Uday P. PratapUPUday P. Pratap
- Xue YangXYXue Yang
- Zexuan LiuZLZexuan Liu
- Kristin A. AltweggKAKristin A. Altwegg
- Bindu SanthammaBSBindu Santhamma
- Kumaraguruparan RamasamyKRKumaraguruparan Ramasamy
- Swapna KondaSKSwapna Konda
- Yidong ChenYCYidong Chen
- Zhao LaiZLZhao Lai
- Siyuan ZhengSZSiyuan Zheng
- Gangadhara R. SareddyGSGangadhara R. Sareddy
Open Access
Abstract
Endometrial cancer (EC) is the fourth most common cancer in women, and half of the endometrioid EC (EEC) cases are attributable to obesity. However, the underlying mechanism(s) of obesity-driven EEC remain(s) unclear. In this study, we examined whether LIF signaling plays a role in the obesity-driven progression of EEC. RNA-seq analysis of EEC cells stimulated by adipose conditioned medium (ADP-CM) showed upregulation of LIF/LIFR-mediated signaling pathways including JAK/STAT and interleukin pathways. Immunohistochemistry analysis of normal and EEC tissues collected from obese patients revealed that LIF expression is upregulated in EEC tissues compared to the normal endometrium. Treatment of both primary and established EEC cells with ADP-CM increased the expression of LIF and its receptor LIFR and enhanced proliferation of EEC cells. Treatment of EEC cells with the LIFR inhibitor EC359 abolished ADP-CM induced colony formation andcell viability and decreased growth of EEC organoids. Mechanistic studies using Western blotting, RT-qPCR and reporter assays confirmed that ADP-CM activated LIF/LIFR downstream signaling, which can be effectively attenuated by the addition of EC359. In xenograft assays, co-implantation of adipocytes significantly enhanced EEC xenograft tumor growth. Further, treatment with EC359 significantly attenuated adipocyte-induced EEC progression in vivo. Collectively, our data support the premise that LIF/LIFR signaling plays an important role in obesity-driven EEC progression and the LIFR inhibitor EC359 has the potential to suppress adipocyte-driven tumor progression.Keywords
Funding Information
- National Institutes of Health (R01CA267893)
- T.E.A.L.®’s 2021 Medical Research Program (170711-44096)
- ThriveWell Cancer Foundation (170722-44096)
- American Cancer Society Research Scholar Grants (132931-RSG-18-187-01-TBG)
- Institutional Research Grants (IRG-21-147-01-IRG)
- Institutional CPRIT Research Training Award (RP170345)
- Cancer Center at UT Health San Antonio (NIH-NCI P30 CA054174)
- NIH Shared Instrument (1S10OD021805-01)
- CPRIT Core Facility Award (RP160732)
This publication has 37 references indexed in Scilit:
- Type I and II Endometrial Cancers: Have They Different Risk Factors?Journal of Clinical Oncology, 2013
- Epigenetic Up-Regulation of Leukemia Inhibitory Factor (LIF) Gene During the Progression to Breast CancerMolecules and Cells, 2011
- Differential expression analysis for sequence count dataGenome Biology, 2010
- TopHat: discovering splice junctions with RNA-SeqBioinformatics, 2009
- Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort studyBMJ, 2007
- Stat3 activation in human endometrial and cervical cancersBritish Journal of Cancer, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Overweight, obesity and cancer: epidemiological evidence and proposed mechanismsNature Reviews Cancer, 2004
- Leukemia Inhibitory Factor Can Substitute for Nidatory Estrogen and Is Essential to Inducing a Receptive Uterus for Implantation But Is Not Essential for Subsequent Embryogenesis1Endocrinology, 2000
- Association and Activation of Jak-Tyk Kinases by CNTF-LIF-OSM-IL-6 β Receptor ComponentsScience, 1994